- Home
- IMCR vs DQ Comparison
IMCR vs DQ Comparison
Compare IMCR & DQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- DQ
- Stock Information
- Founded
- IMCR 2008
- DQ 2006
- Country
- IMCR United Kingdom
- DQ China
- Employees
- IMCR N/A
- DQ N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- DQ Semiconductors
- Sector
- IMCR Health Care
- DQ Technology
- Exchange
- IMCR Nasdaq
- DQ Nasdaq
- Market Cap
- IMCR 1.4B
- DQ 1.4B
- IPO Year
- IMCR 2021
- DQ 2010
- Fundamental
- Price
- IMCR $28.41
- DQ $13.93
- Analyst Decision
- IMCR Buy
- DQ Hold
- Analyst Count
- IMCR 12
- DQ 6
- Target Price
- IMCR $60.90
- DQ $20.31
- AVG Volume (30 Days)
- IMCR 403.7K
- DQ 1.1M
- Earning Date
- IMCR 05-07-2025
- DQ 04-29-2025
- Dividend Yield
- IMCR N/A
- DQ N/A
- EPS Growth
- IMCR N/A
- DQ N/A
- EPS
- IMCR N/A
- DQ N/A
- Revenue
- IMCR $310,202,000.00
- DQ $1,029,080,000.00
- Revenue This Year
- IMCR $20.52
- DQ N/A
- Revenue Next Year
- IMCR $8.57
- DQ $67.31
- P/E Ratio
- IMCR N/A
- DQ N/A
- Revenue Growth
- IMCR 24.36
- DQ N/A
- 52 Week Low
- IMCR $23.15
- DQ $12.90
- 52 Week High
- IMCR $62.74
- DQ $30.85
- Technical
- Relative Strength Index (RSI)
- IMCR 51.56
- DQ 32.68
- Support Level
- IMCR $26.37
- DQ $17.70
- Resistance Level
- IMCR $27.67
- DQ $15.02
- Average True Range (ATR)
- IMCR 1.76
- DQ 1.18
- MACD
- IMCR 0.10
- DQ -0.17
- Stochastic Oscillator
- IMCR 77.93
- DQ 18.76
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About DQ DAQO New Energy Corp.
Daqo New Energy Corp is a polysilicon manufacturer based in China. The company manufactures and sells high-purity polysilicon to manufacturers who use it to make ingots, cells, and modules for solar power solutions. The polysilicon is packaged to meet crucible stacking, pulling, and solidification needs. All of the company's revenues come from the People's Republic of China.